Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05709821
Title IMM60 and Pembrolizumab in Melanoma and NSCLC
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors iOx Therapeutics
Age Groups: adult | senior
Covered Countries USA | GBR | ESP

Facility Status City State Zip Country Details
USC Norris Comprehensive Cancer Center Los Angeles California 90033 United States Details
Dana-Farber Cancer Institute - Medicine Boston Massachusetts 02215 United States Details
Henry Ford Hospital - Internal Medicine Detroit Michigan 48202 United States Details
Rutgers, The State University of New Jersey - Robert Wood Johnson Medical School - The Cancer Institute of New Jersey (CINJ) New Brunswick New Jersey 08901 United States Details
Next VA Fairfax Virginia 22031 United States Details
Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol Badalona Barcelona 08916 Spain Details
Complexo Hospitalario Universitario A Coruña A Coruña Galicia 15006 Spain Details
Hospital Xeral Álvaro Cunqueiro Vigo Pontevedra 36312 Spain Details
Hospital de La Santa Creu i Sant Pau Barcelona 08041 Spain Details
Hospital Universitario 12 de Octubre Madrid 28041 Spain Details
Hospital Regional Universitario de Málaga Málaga 29011 Spain Details
Hospital Universitario Virgen De La Macarena Sevilla 41009 Spain Details
H. Clínico de Valencia Valencia 46010 Spain Details
Nottingham University Hospital - Oncology Nottingham NG5 1PB United Kingdom Details
*Shaded cells indicate that there was no data available from for the field